Carlsberg is celebrating its unique history with the re-launch of six of their its vintage labels, each telling a story of how the Danish beer company has been a first-mover in everything from long beards to international shipping.
From the creators of the pH scale and the first pure brewer’s yeast, the company that donates significant proportions of its earnings to support science, art and culture through the Carlsberg Foundation, and the company for whom phrases like “Open-Source” and “Corporate Social Responsibility” were part of the vocabulary centuries ago…
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7526351-carlsberg-worlds-best-labels/
Carlsberg is celebrating its unique history with the re-launch of six of their its vintage labels, each telling a story of how the Danish beer company has been a first-mover in everything from long beards to international shipping.
From the creators of the pH scale and the first pure brewer’s yeast, the company that donates significant proportions of its earnings to support science, art and culture through the Carlsberg Foundation, and the company for whom phrases like “Open-Source” and “Corporate Social Responsibility” were part of the vocabulary centuries ago…
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7526351-carlsberg-worlds-best-labels/
Carlsberg is celebrating its unique history with the re-launch of six of their its vintage labels, each telling a story of how the Danish beer company has been a first-mover in everything from long beards to international shipping.
From the creators of the pH scale and the first pure brewer’s yeast, the company that donates significant proportions of its earnings to support science, art and culture through the Carlsberg Foundation, and the company for whom phrases like “Open-Source” and “Corporate Social Responsibility” were part of the vocabulary centuries ago…
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7526351-carlsberg-worlds-best-labels/
As part of an ongoing commitment to support life sciences innovators and the development of integrated, cross-sector solutions to prevent, intercept and cure diseases, Johnson & Johnson today named cell biologist Yoshinori Ohsumi, Ph.D., of the Tokyo Institute of Technology the winner of the 2016 Dr. Paul Janssen Award for Biomedical Research for his pioneering discoveries concerning the molecular basis of autophagy.
Dr. Ohsumi was honored today during an event at the 2016 BIO International Convention in San Francisco. A video of his acceptance comments can be viewed here.
“Dr. Ohsumi’s curiosity led him to become the first person in the world to determine the molecular mechanism and regulation of autophagy, shedding light on one of the most basic functions of all living cells,” said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson. “Dr. Ohsumi’s discoveries hold promise for better understanding, preventing and treating many diseases. It is with great pleasure that we celebrate his contributions, which remind us of the innovative spirit Dr. Paul brought to the lab every day.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7856351-2016-dr-paul-janssen-award-ohsumi/
Combining their expertise in clinical trials support and cellular therapies, BloodCenter of Wisconsin (BCW) and the San Diego Blood Bank (SDBB) have created a strategic partnership to accelerate advancements in research and patient care. Together, BloodCenter of Wisconsin and San Diego Blood Bank will offer Celluvative™ – a portfolio of products and clinical trial services that will include esoteric laboratory testing, blood products for research and manufacturing applications, cell processing, and access to a broad database of diverse donors who have expressed interest in clinical trials.
“Through the strength of our partnership, we are able to offer end-to-end services to academic organizations, research institutions and other industry partners who are working to develop novel cellular therapy approaches,” said Matthew Anderson, M.D., Ph.D., medical director, BloodCenter of Wisconsin Diagnostic Laboratories. “Among other offerings, our Celluvative portfolio enables access to an extremely diverse donor database – an invaluable resource to enable advances in the area of regenerative medicine and drug discovery.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7855451-bloodcenter-sdbb-celluvative/
Lustgarten Foundation funded researchers at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins have designed a multi-analyte blood test that can detect the presence of pancreatic cancer as part of a panel of eight common cancers (pancreas, ovary, liver, stomach, esophagus, colorectum, lung and breast) as reported in the online edition of Science today. The test utilizes combined assays for genetic alterations and protein biomarkers and has the capacity not only to identify the presence of relatively early cancer, but also to localize the organ of origin of these cancers.
“The potential this has for pancreatic cancer is unprecedented,” says Anne Marie Lennon, M.D., Ph.D., Associate Professor of Medicine, Director, Pancreatic Cyst Center of the Ludwig Center at the Johns Hopkins Kimmel Cancer Center. “We know that in 80-85 percent of pancreatic cancer cases, it’s detected too late, leaving the patient with few options. Developing a blood screening test for pancreatic cancer has been an urgent goal, because catching the disease early will be the way we get to long-term survival.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8213751-lustgarten-foundation-pancreatic-cancer-blood-test/
Don’t trust us, trust Science: Abbott is among the best science-based companies to work for in the world.
For the 13th consecutive year, the journal Science today recognized Abbott on its Top Employers list, evaluated on 23 characteristics including financial strength, easy adaptation to change and a having a research-driven environment.
”Abbott is unique in that we’ve been adding to our reservoir of scientific knowledge for 128 years,“ said John Frels, Ph.D., chair of Abbott’s Scientific Governing Board, which oversees the company’s senior scientific career track. ”We strive to bring in the best and brightest scientists and engineers to work on some of the biggest problems in healthcare today. This helps us to create new, breakthrough innovations that change people’s lives.“
To view the multimedia release go to:
http://www.multivu.com/players/English/7962251-science-names-abbott-2016-top-employer/
Soy consumption is up 14 percent since 2011,26 yet confusion lingers over soy’s role in everything from human health to food production. To clear up misperceptions, the United Soybean Board (USB) busts five common soy myths with science-backed facts on SoyConnection.com/soy-wisdom.
1) Eating soy does not increase breast cancer risk.
Clinical studies show soy isoflavone exposure does not adversely affect breast tissue as assessed by markers of breast cancer risk, such as breast cell proliferation.1–7 The American Institute for Cancer Research and the American Cancer Society say that women who have been diagnosed with breast cancer can safely consume soyfoods. In fact, the World Cancer Research Fund International has identified a link between soy consumption and an improved survival of breast cancer patients.8-9
“Not only does evidence indicate soyfoods may benefit women with breast cancer, but consuming soy when young helps prevent the onset of this disease later in life27-30,” stated Mark Messina, Ph.D., who has dedicated the past 30 years to understanding the health effects of soyfoods.
To view the multimedia release go to:
http://www.multivu.com/players/English/7877951-united-soybean-board-top-soy-myths/
A new online resource is now available to help people recognize and find high quality care for alcohol use disorder, which affects more than 15 million adults in the United States. The Alcohol Treatment Navigator, designed by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the National Institutes of Health, is a comprehensive, yet easy-to-use tool to help individuals and their loved ones navigate the often-complicated process of choosing treatment for alcohol problems. With many treatment options available, the navigator makes the search easier by telling them what they need to know - and what they need to do – to find appropriate, quality care.
“We developed this tool to help address the alcohol ‘treatment gap,’” said NIAAA Director George F. Koob, Ph.D. “In any given year, less than 10 percent of individuals diagnosed with alcohol use disorder receive treatment, and many of them do not receive the type of care that best fits their needs. A big reason for that, we believe, is that people with alcohol use disorder often don’t know where to turn for help. The Alcohol Treatment Navigator offers a comprehensive strategy to help people search for professionally-led, evidence-based alcohol treatment, which should improve their chances for success.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8179051-niaaa-alcohol-treatment-navigator/
Eli Lilly and Company (NYSE: LLY) will commemorate its 140th anniversary today with activities at Lilly locations worldwide, including a ceremony to unveil a statue dedicated to founder Colonel Eli Lilly at global headquarters in Indianapolis.
Over 14 decades, the organization has contributed more than 100 medicines and significant medical advances, such as the first commercially available insulin, manufacturing and global distribution of the Salk polio vaccine and mental health breakthroughs such as anti-depressant Prozac® (fluoxetine). Today Lilly continues to progress its most robust pipeline in history with dozens of potential new medicines in mid- to late-stage development for cancer, diabetes, autoimmune disease, pain and Alzheimer’s disease.
“As Lilly celebrates 140 years, we’re keeping the vision of our founder alive – from our dedication in the lab to our impact in the community,” said John C. Lechleiter, Ph.D., Lilly chairman, president and chief executive officer, who began his career at Lilly as a chemist in 1979. “Colonel Eli Lilly started this company to put science to work fighting disease and encouraged his successors to ‘take what you find here and make it better and better.’ That vision pushes us daily to honor Colonel Lilly’s legacy and continue in our quest to discover new medicines to help make life better.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7809951-eli-lilly-and-company-140th-anniversary/
On the eve of World Cancer Day 2015, amidst the ongoing cost-of-cancer-care debate, PACE (Patient Access to Cancer care Excellence), a Lilly Oncology initiative, is launching the PACE Continuous Innovation Indicators™ (CII). CII is the first evidence-based, customizable online tool to review progress against cancer over time—initially covering 12 cancer types. The purpose of the tool is to inform public policy reforms and other efforts to accelerate continuous innovation against cancer.
“We have seen tremendous progress in cancer treatment and care during the past decades, and continuous innovation, with one discovery building on another, is responsible for most of it,” said John C. Lechleiter, Ph.D., Chairman, President, and Chief Executive Officer of Eli Lilly and Company (NYSE:LLY). “To keep the momentum going, we need policies that support continuous innovation, but first we need a deeper understanding of the innovations that have occurred, and where we need to be.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7419451-eli-lilly-oncology-pace/
Changes in the treatment of pediatric cancer over recent decades have translated to a reduced risk of serious, long-term late health effects of cancer therapy. This is according to the latest analysis from the Childhood Cancer Survivor Study (CCSS), a National Cancer Institute-funded resource for late-effects research, led by investigators at St. Jude Children’s Research Hospital.
“This is the first comprehensive study to demonstrate how changes in treatments over time have impacted the occurrence of late effects experienced by childhood cancer survivors,” said Todd Gibson, Ph.D., assistant member of the Department of Epidemiology and Cancer Control at St. Jude. “We found the 15-year cumulative incidence of people reporting at least one severe health condition decreased from 12.7 percent among childhood cancer survivors diagnosed in the 1970s to 10.1 percent for those diagnosed in the 1980s to 8.8 percent in the 1990s–a statistically significant decline.”
To view the multimedia release go to:
https://www.multivu.com/players/English/7924756-st-jude-childhood-cancer-survivorship-asco-2017/
